Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
Buy | Overweight | Hold | Underweight | Sell |
---|---|---|---|---|
20 | 5 | 2 | 0 | 0 |
Analyst Firms Making Recommendations1
- HC Wainwright & Co.
- B of A Securities
- Cantor Fitzgerald
- Wells Fargo
- Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Karuna Therapeutics
What is the target price for Karuna Therapeutics (KRTX)?
The latest price target for Karuna Therapeutics (NASDAQ: KRTX) was reported by HC Wainwright & Co. on September 28, 2023. The analyst firm set a price target for $300.00 expecting KRTX to rise to within 12 months (a possible 77.42% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Karuna Therapeutics (KRTX)?
The latest analyst rating for Karuna Therapeutics (NASDAQ: KRTX) was provided by HC Wainwright & Co., and Karuna Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Karuna Therapeutics (KRTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karuna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karuna Therapeutics was filed on September 28, 2023 so you should expect the next rating to be made available sometime around September 28, 2024.
Is the Analyst Rating Karuna Therapeutics (KRTX) correct?
While ratings are subjective and will change, the latest Karuna Therapeutics (KRTX) rating was a reiterated with a price target of $0.00 to $300.00. The current price Karuna Therapeutics (KRTX) is trading at is $169.09, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.